全球荟萃分析:注射吸毒者中HIV、HCV和HBV感染的性别差异是否随国家层面指标变化?
该荟萃分析按性别估计了全球、区域及国家层面注射吸毒者(PWID)中血清学确诊的HIV、HCV(抗-HCV抗体)和HBV(HBsAg)患病率,并探讨性别差异与国家层面患病率及不平等指标的关系。结果显示性别差异因国家和区域而异:撒哈拉以南非洲和南亚女性HIV患病率高于男性,中东和北非及东亚/东南亚女性抗-HCV低于男性;性别差异随一般人群BBV患病率、人类发展和收入分配而变化。结论提示部分国家女性PWID的HIV风险更高,需制定性别敏感的减害服务。
要点
- 撒哈拉以南非洲女性PWID的HIV风险是男性的2.8倍(RR 2.8,95%CI 1.8-4.4)。
- 南亚女性PWID的HIV风险是男性的1.7倍(RR 1.7,95%CI 1.1-2.7)。
核心结论
- 部分国家女性注射吸毒者的HIV患病率高于男性,但区域间和区域内存在差异。
- 在女性风险更高的国家,需为边缘化的女性注射吸毒人群制定性别敏感的减害服务。
研究设计与样本
- 全球荟萃分析,按性别估计国家、区域和全球注射吸毒者中血清学确诊的HIV、HCV(抗-HCV抗体)和HBV(HBsAg)患病率。
- 将性别间BBV患病率差异(女性相对男性的风险)对国家层面患病率及不平等指标(性别不平等指数、人类发展指数、基尼系数、国家收入水平)进行回归分析。
主要发现
- HIV患病率女性高于男性见于撒哈拉以南非洲(RR 2.8;95%CI 1.8-4.4)和南亚(RR 1.7;95%CI 1.1-2.7)。
- 性别差异随一般人群BBV患病率、人类发展和收入分配的国家水平而变化。
临床怎么用
- 在女性PWID HIV风险更高的国家,应提供性别敏感的减害服务。
- 关注国家层面不平等指标对BBV性别差异的影响,指导针对性干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women-specific factors exist that increases vulnerability to drug-related harms from injection drug use, including blood-borne viruses (BBVs), but gender-based differences in BBV prevalence have not been systematically examined. METHODS: We conducted meta-analyses to estimate country, regional, and global prevalence of serologically confirmed human immunodeficiency virus (HIV), hepatitis C virus (HCV; based on detection of anti-HCV antibody), and hepatitis B virus (HBV; based on detection of HBV surface antigen) in people who inject drugs (PWID), by gender. Gender-based differences in the BBV prevalence (calculated as the risk among women relative to the risk among men) were regressed on country-level prevalence and inequality measures (Gender inequality index, Human development index, Gini coefficient, and high, low or middle income of the country). RESULTS: Gender-based differences varied by countries and regions. HIV prevalence was higher among women than men in sub-Saharan Africa (relative risk [RR], 2.8; 95% confidence interval [CI], 1.8-4.4) and South Asia (RR, 1.7; 95% CI, 1.1-2.7); anti-HCV was lower among women in the Middle East and North Africa (RR, 0.6; 95% CI, .5-.7) and East and Southeast Asia (RR, 0.8; 95% CI, .7-.9). Gender-based differences varied with country-levels of the BBV prevalence in the general population, human development, and income distribution. CONCLUSION: HIV was more prevalent in women who inject drugs as compared to their male counterparts in some countries, but there is variation between and within regions. In countries where women are at higher risks, there is a need to develop gender-sensitive harm-reduction services for the particularly marginalized population of women who inject drugs.
引用
- Leung J, Peacock A, Colledge S, et al. A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs-Do Gender-Based Differences Vary by Country-Level Indicators? J Infect Dis. 2019. PMID: 30726973. doi:10.1093/infdis/jiz058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。